When compared between NASH (n = 94, 51.4%) and non-NASH (n = 89, 48.6%) group, ALT level, LS value, and CAP value were significantly higher in patients with NASH than those with non-NASH (all P<0.05). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.